---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-091172"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:45:58.004590+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# InMed files PCT patent application for INM-901 treating Alzheimer's and neurodegeneration

## Summary
- PCT patent covers composition, method of use for INM-901 in neurodegenerative diseases including Alzheimer's.
- Patent claims neuroprotection, neurite elongation, cognitive/memory improvement, and anti-inflammatory effects.
- InMed now has 14 patent families; eight on drug composition/formulations, six on manufacturing technologies.
- Company plans to present long-term in vivo data for INM-901 in coming weeks.
- INM-901 is an oral small molecule with CB1/CB2 and PPAR activity, targeting multiple Alzheimer's pathways.

## SEC filing metadata
- accession: 0001213900-24-091172
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024091172/0001213900-24-091172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024091172/ea0218824-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-091172
- JSON: https://secwatch.observer/filing/0001213900-24-091172.json
- Plain text: https://secwatch.observer/filing/0001213900-24-091172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.